. Author manuscript; available in PMC: 2019 Nov 13.

Published in final edited form as: Cardiovasc Intervent Radiol. 2018 May 15;41(9):1419–1427. doi: 10.1007/s00270-018-1985-1

Table 4.

Grade 1–2 toxicities

Complication (multiple possible per patient)	Study group	Control group

Fatigue/weakness	5/22 (23%)	26/58 (45%)
Abdominal pain/distension	3/22 (14%)	17/58 (29%)
Shortness of breath	1/22 (5%)	9/58 (16%)
Fever	1/22 (5%)	9/58 (16%)
Change in appetite/weight changes	0	8/58 (14%)
Nausea	1/22 (5%)	7/58 (12%)
Vomiting	0	4/58 (7%)
Ascites	0	5/58 (9%)
Constipation/diarrhea	0	13/58 (45%)
Light colored stool/dark urine	0	9/58 (16%)
Hiccups	0	1/58 (2%)
Portal hypertension	1/22 (5%)	0
Total patients number	8/22 (36%)	26/58 (45%)